Monoclonal antibody development has become a cornerstone of modern biopharmaceutical research, offering highly targeted therapies for a wide range of diseases. From oncology and autoimmune disorders to infectious diseases, monoclonal antibodies (mAbs) provide specificity and precision that traditional small-molecule drugs often cannot achieve. As the demand for biologics continues to grow, the importance of efficient and scalable monoclonal antibody development processes has never been greater. Understanding Monoclonal Antibodies Monoclonal antibodies are laboratory-produced molecules designed to bind to a specific antigen. They are derived from a single clone of B cells, ensuring uniformity and high specificity toward a particular target. This precision allows them to identify and attach to unique proteins expressed on the surface of pathogens or diseased cells. The concept of monoclonal antibodies was first introduced in the 1970s and later recognized with a Nobel Prize awarde...